A61K 2239/30
Mixture of cells
A61K2239/30 (Mixture of cells) appears on 5 US grants and 30 published applications in this corpus.
Search patents in A61K- Granted patents
- 5
- Published applications
- 30
- Assignees
- 30
- Inventors
- 98
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 0 | 2 |
| 2022 | 0 | 3 |
| 2023 | 2 | 7 |
| 2024 | 0 | 6 |
| 2025 | 1 | 8 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Vaccine and uses thereof in cell therapy18 Aug 2026US 12,708,672 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Fratricide resistant modified immune cells and methods of using the same17 Mar 2026US 12,576,151 B2Beam Therapeutics Inc.
- Combining iPSC derived effector cell types for immunotherapy use15 Apr 2025US 12,275,955 B2Fate Therapeutics, Inc.
- Antigen receptors and uses thereof18 Jul 2023US 11,702,631 B2BioNTech Cell & Gene Therapies GmbH
- Vaccine and uses thereof in cell therapy25 Apr 2023US 11,633,427 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Chimeric antigen receptor16 Jul 2026US 2026/0201068 A1Les Hopitaux Universitaires De Geneve
- Methods for Generating Engineered Lymphocytes11 Dec 2025US 2025/0375480 A1Kite Pharma, Inc.
- Compositions and systems for combinatorial therapies containing fucosylated cells and immune checkpoint inhibitors and methods of production and use thereof11 Dec 2025US 2025/0375523 A1Targazyme, Inc.
- Specific t cell for preventing or treating cancer, and preparation method thereof9 Oct 2025US 2025/0313801 A1Suzhou Ersheng Biomedical Co., Ltd.
- Combining ipsc derived effector cell types for immunotherapy use9 Oct 2025US 2025/0313802 A1Fate Therapeutics, Inc.
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.